Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01627327 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
NCT01627327 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 623 participants.
The verdict
NCT01627327, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a 12-week treatment period in subjects with COPD who have or are at risk for co-morbid cardiovascular disease
Interventions
- DRUG fluticasone furoate/vilanterol 100/25mcg
- DRUG tiotropium bromide 18mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2012-04-01 |
| Est. Completion | 2012-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01627327
The ClinicalTrials.gov registry entry for NCT01627327 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fluticasone furoate/vilanterol 100/25mcg is the first listed.
NCT01627327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01627327 about?
NCT01627327 is a clinical study titled "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease". The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a 12-week treatment period in subjects with COPD who have or are at risk for...
What is the current status of trial NCT01627327?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2012-04-01. Estimated completion is 2012-12-21.
What interventions are being tested in trial NCT01627327?
The interventions under investigation include: fluticasone furoate/vilanterol 100/25mcg (DRUG), tiotropium bromide 18mcg (DRUG).
Who is sponsoring clinical trial NCT01627327?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.